Hezel Aram F, Ryan David P
Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
Expert Opin Investig Drugs. 2007 Jun;16(6):867-76. doi: 10.1517/13543784.16.6.867.
Colorectal carcinoma is a leading cause of cancer mortality worldwide. Survival for patients with metastatic disease is approximately 2 years on average and there is an ongoing need for the identification of new therapeutic agents. As the cancer research community has appreciated, newly discovered pathways governing cancer cell growth, survival, apoptosis, invasion and angiogenesis--all a host of potential therapeutic targets--have come into view. Basic research, preclinical data and observations arising from early stage trials have pointed towards possible roles for many of these agents in the future treatment of colorectal cancer. In this review, the authors summarize agents in development, modulating several of the most promising molecules and pathways that are thought to be relevant to colorectal cancer.
结直肠癌是全球癌症死亡的主要原因。转移性疾病患者的平均生存期约为2年，因此持续需要鉴定新的治疗药物。随着癌症研究界的认识，新发现的调控癌细胞生长、存活、凋亡、侵袭和血管生成的途径——所有这些都是潜在的治疗靶点——已逐渐显现。基础研究、临床前数据以及早期试验的观察结果表明，这些药物中的许多在未来结直肠癌治疗中可能发挥作用。在这篇综述中，作者总结了正在研发的药物，这些药物调节了几种最有前景的、被认为与结直肠癌相关的分子和途径。
